{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:06:09Z","timestamp":1776888369066,"version":"3.51.2"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vaccines developed using modified messenger RNA (mRNA) technology show robust efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans. However, viral evolution in human and non-human hosts may compromise vaccine performance due to the emergence of new variants with strong immune-escape abilities. Therefore, a coronavirus disease 2019 (COVID-19) vaccine that induces high levels of broadly neutralizing antibodies (bnAbs) and responds quickly to viral mutations is urgently required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, we designed a bivalent mRNA vaccine, RBDco, based on the variant of concern (VOC) spike (S) protein receptor-binding domain (RBD) chimeric from different lineages fused with Fc fragments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In mice and non-human primates, RBDco effectively induced neutralizing antibodies against several pseudoviruses, including the possible epidemic variants XBB.1, XBB.1.9.1, and EA.1 pseudoviruses. In mice, RBDco induced bnAbs against 11 SARS-CoV-2 variant pseudoviruses from different lineages. The neutralizing antibody titers against the prototype D614G and the epidemic variant XBB.1.16 were 19666 and 13274, respectively. RBDco induced mice secrete interferon-\u03b3 (IFN-\u03b3) under the stimulation of RBD proteins of SARS-CoV-2 variants. In the mouse challenge model, RBDco treatment led to a 10-fold reduction in the viral load in the lungs of mice after the challenge. These results suggest that RBDco can induce a bnAb response and cellular immune response in animals, thereby preventing the occurrence of COVID-19. Furthermore, the sequential immunization results showed an improved neutralizing antibody titer in RBDco-boosted groups relative to the inactivated group. Enhanced differentiation of memory T cells was observed in the RBDco-boosted group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Overall, RBDco can induce bnAbs in animals via chimeric RBDs with the SARS-CoV-2 VOC in different lineages and is a candidate for mRNA vaccine for a rapid response to viral mutations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1543212","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T01:28:01Z","timestamp":1743125281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or coronaVac vaccine recipients","volume":"75","author":"Lu","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/microorganisms12010089","article-title":"Vaccinating against a novel pathogen: A critical review of COVID-19 vaccine effectiveness evidence","volume":"12","author":"Black","year":"2023","journal-title":"Microorganisms"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/v15040944","article-title":"Evolution of SARS-coV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies","volume":"15","author":"Zabidi","year":"2023","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.884","article-title":"The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health","volume":"5","author":"Islam","year":"2022","journal-title":"Health Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.093195","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"590","author":"Van Doremalen","year":"2021","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01596-22","article-title":"Targeting the spike receptor binding domain class V cryptic epitope by an antibody with pan-sarbecovirus activity","volume":"97","author":"Jensen","year":"2023","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.61320","article-title":"Receptor-binding domain of SARS-CoV-2 spike protein efficiently inhibits SARS-CoV-2 infection and attachment to mouse lung","volume":"17","author":"Shin","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","article-title":"Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2","volume":"185","author":"Xu","year":"2022","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine","volume":"324","author":"He","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01020-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults","volume":"61","author":"Yu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-coV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"nwab167","DOI":"10.1093\/nsr\/nwab167","article-title":"Transient acquisition of cross-species infectivity during the evolution of SARS-CoV-2","volume":"8","author":"Chen","year":"2021","journal-title":"Natl Sci Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/ten.tea.2017.0485","article-title":"Maximizing the translational yield of mRNA therapeutics by minimizing 5\u2019-UTRs","volume":"25","author":"Trepotec","year":"2019","journal-title":"Tissue Eng Part A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A Thermostable mRNA Vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly neutralizing antibodies for HIV-1 prevention","volume":"12","author":"Walsh","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12929-023-00955-x","article-title":"Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2","volume":"30","author":"Chiang","year":"2023","journal-title":"J BioMed Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752003","article-title":"Broadly-neutralizing antibodies against emerging SARS-coV-2 variants","volume":"12","author":"Shrestha","year":"2021","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0839","article-title":"Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models","volume":"377","author":"Cohen","year":"2022","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.18.572191","article-title":"Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates","author":"Malewana","year":"2023","journal-title":"bioRxiv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03594-0","article-title":"Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses","volume":"594","author":"Saunders","year":"2021","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.23.541980","article-title":"Antigen spacing on protein nanoparticles influences antibody responses to vaccination","author":"Ellis","year":"2023","journal-title":"bioRxiv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.chom.2023.07.004","article-title":"Rational design of a booster vaccine against COVID-19 based on antigenic distance","volume":"31","author":"Hu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B37","doi-asserted-by":"publisher","first-page":"113553","DOI":"10.1016\/j.celrep.2023.113553","article-title":"Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses","volume":"42","author":"Dosey","year":"2023","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4235","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jmp.12630","article-title":"Measles in non-human primates","volume":"52","author":"Dogadov","year":"2023","journal-title":"J Med Primatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"121570","DOI":"10.1016\/j.biomaterials.2022.121570","article-title":"An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates","volume":"286","author":"Ripoll","year":"2022","journal-title":"Biomaterials"},{"key":"B43","doi-asserted-by":"publisher","first-page":"120868","DOI":"10.1016\/j.biomaterials.2021.120868","article-title":"Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates","volume":"275","author":"Martin","year":"2021","journal-title":"Biomaterials"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01505-9","article-title":"Immune imprinting and next-generation coronavirus vaccines","volume":"8","author":"Huang","year":"2023","journal-title":"Nat Microbiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.immuni.2023.07.007","article-title":"SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals","volume":"56","author":"Sokal","year":"2023","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerging Microbes infections"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast","volume":"22","author":"Kent","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf7517","article-title":"T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals","volume":"13","author":"Bilich","year":"2021","journal-title":"Sci Trans Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000638","article-title":"Recent insights into Fc-mediated effector responses to HIV-1","volume":"15","author":"Carpenter","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000644","article-title":"Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV","volume":"15","author":"Danesh","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02968","article-title":"Update on fc-mediated antibody functions against HIV-1 beyond neutralization","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0065-2776(09)03004-1","article-title":"Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn","volume":"103","author":"Ward","year":"2009","journal-title":"Adv Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2023_030","article-title":"COVID-19 vaccine immunity in oncology patients","volume":"124","author":"Uslu","year":"2023","journal-title":"Bratisl Lek Listy"},{"key":"B59","article-title":"COVID-19 Booster Vaccine: is it an absolute need","volume":"19","author":"Ghimire","year":"2021","journal-title":"Kathmandu Univ Med J (KUMJ)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/23744235.2021.1974540","article-title":"Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination","volume":"54","author":"Soeorg","year":"2022","journal-title":"Infect Dis (Lond)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1543212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T01:28:07Z","timestamp":1743125287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1543212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2025.1543212"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1543212","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1543212"}}